从奥妥珠单抗静脉输液反应的预防、奥妥珠单抗静脉输液反应的处理等方面总结145例恶性淋巴细胞增殖性疾病患者行90 min静脉快速输注奥妥珠单抗静脉输液反应的护理经验。所有患者于治疗的第1周期均采用奥妥珠单抗标准输注方案，针对第1周期未发生≥3级输液反应的患者，从第2周期开始采用90 min奥妥珠单抗快速输注方案。145例患者共接受730次奥妥珠单抗治疗，其中行快速输注方案583次。在标准输注过程中，共17例（11.72%）患者发生输液反应，其中3级输液反应3例（2.07%）。在快速输注过程中，仅1例（0.70%）患者发生1级输液反应。该方法具有可行性和便利性，建议加强奥妥珠单抗用药相关的护士培训，以便临床推广应用。

To summarize the nursing experience of 145 patients with malignant lymphoproliferative disease who received 90-minute intravenous infusion of obinutuzumab from the aspects of the prevention and treatment of obinutuzumab intravenous infusion reaction.All patients were treated with obinutuzumab standard infusion regimen in the first cycle of treatment.For patients who did not experience ≥ grade 3 infusion reactions in the first cycle，a 90-minute rapid infusion regimen of obinutuzumab was used from the second cycle.A total of 145 patients received 730 infusions of obinutuzumab，including 583 infusions of rapid infusion.During the standard infusion，a total of 17 patients (11.72%) had infusion reactions，including 3 patients (2.07%) with grade 3 infusion reactions.During the rapid infusion，only 1 patient (0.70%) had grade 1 infusion reaction.This method is feasible and convenient.It is suggested to strengthen the nurse training of obinutuzumab medication so as to promote it in the clinical context.

R473.55

江苏省医学创新团队项目（CXTDA2017019）；江苏省人民医院临床能力提升护理项目（JSPH-NC-2021-09）